CSIMarket
 


Immunome Inc  (IMNM)
Other Ticker:  
 

Immunome Inc's Quick Ratio

IMNM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Immunome Inc's Cash & cash equivalent grew by 104.04 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Immunome Inc's Quick Ratio to 3.92, Quick Ratio remained below Immunome Inc average.

Within Major Pharmaceutical Preparations industry 223 other companies have achieved higher Quick Ratio than Immunome Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 714, from total ranking in the first quarter 2023 at 1255.

Explain Quick Ratio?
How much Cash & cash equivalents IMNM´s has?
What are IMNM´s Current Liabilities?


IMNM Quick Ratio (Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Current Liabilities Change 564.68 % 452.66 % 150.63 % 36.31 % -
Y / Y Cash & cash equivalent Change 51.5 % 22.46 % -48.89 % 301.51 % -
Quick Ratio MRQ 3.92 1.79 2.77 3.67 17.21
IMNM's Total Ranking # 714 # 1255 # 727 # 0 #
Seq. Current Liabilities Change -6.93 % 238.71 % -0.52 % 111.94 % -22.61 %
Seq. Cash & cash equivalent Change 104.04 % 118.59 % -24.95 % -54.74 % 64.93 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 224
Healthcare Sector # 382
Overall Market # 714


Quick Ratio Statistics
High Average Low
17.21 6.54 1.25
(Jun 30 2021)   (Sep 30 2020)




Financial Statements
Immunome Inc's Current Liabilities $ 23 Millions Visit IMNM's Balance sheet
Immunome Inc's Cash & cash equivalent $ 91 Millions Visit IMNM's Balance sheet
Source of IMNM's Sales Visit IMNM's Sales by Geography


Cumulative Immunome Inc's Quick Ratio

IMNM's Quick Ratio for the trailling 12 Months

IMNM Quick Ratio

(Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Current Liabilities TTM Growth 564.68 % 452.66 % 150.63 % 36.31 % -
Y / Y Cash & cash equivalent TTM Growth 51.5 % 22.46 % -48.89 % 301.51 % -
Quick Ratio TTM 2.91 3.53 6.33 8.92 8.75
Total Ranking TTM # 3543 # 3926 # 1922 # 0 #
Seq. Current Liabilities TTM Growth -6.93 % 238.71 % -0.52 % 111.94 % -22.61 %
Seq. Cash & cash equivalent TTM Growth 104.04 % 118.59 % -24.95 % -54.74 % 64.93 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the III Quarter 2023 to $23.11 millions, cumulative Quick Ratio decreased to 2.91 below the Immunome Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 474 other companies have achieved higher Quick Ratio than Immunome Inc. While Quick Ratio overall ranking has improved so far to 3543, from total ranking during the twelve months ending first quarter 2023 at 3926.

Explain Quick Ratio?
How much Cash & cash equivalents IMNM´s has?
What are IMNM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 475
Healthcare Sector # 975
Within the Market # 3543


trailing twelve months Quick Ratio Statistics
High Average Low
8.81 5.4 2.47
(Sep 30 2022)   (Dec 31 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Atai Life Sciences N v   10.77 $ 208.994  Millions$ 19.403  Millions
Nkarta Inc   10.75 $ 275.613  Millions$ 25.640  Millions
Lipocine Inc   10.64 $ 23.848  Millions$ 2.241  Millions
Kinnate Biopharma Inc   10.62 $ 167.576  Millions$ 15.774  Millions
Caladrius Biosciences Inc   10.60 $ 54.394  Millions$ 5.132  Millions
Pasithea Therapeutics Corp   10.53 $ 19.680  Millions$ 1.869  Millions
Cryoport inc   10.41 $ 467.518  Millions$ 44.905  Millions
Structure Therapeutics Inc   10.22 $ 205.424  Millions$ 20.091  Millions
Actinium Pharmaceuticals Inc   10.18 $ 82.978  Millions$ 8.150  Millions
89bio Inc   9.99 $ 251.926  Millions$ 25.212  Millions
Lianbio  9.84 $ 252.222  Millions$ 25.627  Millions
Virios Therapeutics Inc   9.82 $ 4.786  Millions$ 0.487  Millions
Annexon Inc   9.63 $ 165.271  Millions$ 17.170  Millions
Syndax Pharmaceuticals Inc   9.54 $ 373.821  Millions$ 39.174  Millions
Milestone Pharmaceuticals inc   9.34 $ 75.746  Millions$ 8.114  Millions
Adicet Bio Inc   9.27 $ 183.257  Millions$ 19.768  Millions
Reneo Pharmaceuticals Inc   9.26 $ 125.614  Millions$ 13.563  Millions
Aerovate Therapeutics Inc   9.18 $ 135.199  Millions$ 14.725  Millions
Xenetic Biosciences Inc   9.15 $ 9.776  Millions$ 1.069  Millions
Werewolf Therapeutics Inc   9.01 $ 130.058  Millions$ 14.439  Millions
Igm Biosciences Inc   9.01 $ 386.991  Millions$ 42.965  Millions
Cytokinetics Incorporated  8.91 $ 539.239  Millions$ 60.487  Millions
Phathom Pharmaceuticals Inc   8.91 $ 213.677  Millions$ 23.979  Millions
Generation Bio Co   8.87 $ 291.025  Millions$ 32.819  Millions
Point Biopharma Global Inc   8.77 $ 339.163  Millions$ 38.666  Millions
Zentalis Pharmaceuticals Inc   8.77 $ 516.637  Millions$ 58.918  Millions
Bullfrog Ai Holdings Inc   8.64 $ 3.856  Millions$ 0.446  Millions
Spruce Biosciences Inc   8.59 $ 108.032  Millions$ 12.572  Millions
Cerevel Therapeutics Holdings Inc   8.59 $ 676.882  Millions$ 78.838  Millions
Tff Pharmaceuticals Inc   8.52 $ 9.726  Millions$ 1.142  Millions

Date modified: 2023-11-30T10:24:58+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com